Illumina CEO Talks Future of Array Market, Manufacturing Expansion at UBS Conference
September 21, 2010
Illumina CEO Talks Future of Array Market, Manufacturing Expansion at UBS Conference
The array market is set to grow to $900 million by 2013 and Illumina hopes to capture its share with next-generation genotyping arrays for future GWAS. But high demand for the firm's chips and instruments has led to manufacturing constraints that it is now working to overcome.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent
May 3, 2011 / BioArray News - Array Orders Surge for Illumina in Q4, But Revenues Slip Due to Manufacturing Constraints
February 14, 2012 / BioArray News - Affymetrix Restructures as Q3 Revenues Drop 14 Percent on Weak Product Sales
November 8, 2011 / BioArray News - 'Soft' Q1 Pushes Affymetrix to Bet on Applied Markets, Acquisitions to Restore Growth
May 3, 2011 / BioArray News - Analysts Predict 'Muted' Array Demand in 2011, Cut Expectations for Illumina
March 22, 2011 / BioArray News